ROAD TOWN, British Virgin Islands, Aug. 02, 2025 (GLOBE NEWSWIRE) -- The recent Ethereum bull run has renewed momentum across the blockchain space, drawing increased attention to emerging platforms that combine utility with innovation. Among them, Ozak AI is gaining investor interest as it announces the launch of Stage 4 of its $OZ token presale, now priced at $0.005.
ROAD TOWN, British Virgin Islands, Aug. 01, 2025 (GLOBE NEWSWIRE) -- OZAK AI Raises above $1,500,000 in Presale and it’s currently priced at $0.005. Visa’s growing interest in stablecoins has shifted the focus toward AI-integrated cryptocurrencies. Ozak AI is one among them and is rapidly developing attention. Its ongoing presale has already sold over 66.2 million tokens and raised over 1.53 million.
ROAD TOWN, British Virgin Islands, Aug. 01, 2025 (GLOBE NEWSWIRE) -- OZAK AI has made a significant impact in the crypto and AI investment sector. It is capturing serious attention after completing its Certik audit (considered to be the best benchmark of security in blockchain projects worldwide) and raising over $1.5 million, with its presale ongoing, at just $0.005 per token.
BEIJING, July 31, 2025 /PRNewswire/ -- WeRide (Nasdaq: WRD), a global leader in autonomous driving technology, announced its financial results for Q2 2025 on...
BEIJING, July 31, 2025 /PRNewswire/ -- WeRide (Nasdaq: WRD), a global leader in autonomous driving technology, announced its financial results for Q2 2025 on...
New York, NY, July 31, 2025 (GLOBE NEWSWIRE) -- The Ether Machine, the ether generation company, announced yesterday that The Ether Reserve LLC has purchased nearly 15,000 ETH at $3,809.97 USD for a total of $56,900,000.01 USD as part of The Ether Machine’s long-term accumulation strategy. This brings total ETH purchased and committed to 334,757 with up to $407,000,000 of USD remaining for additional ETH purchases.
Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company’s ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY, OR CONSTITUTE A VIOLATION OF, THE RELEVANT LAWS OF THAT JURISDICTION OR REQUIRE EURONEXT AND/OR ATHEX TO TAKE ANY FURTHER ACTION.
SETOUCHI, Japan, July 31, 2025 /PRNewswire/ -- The Setouchi Triennale is an essential celebration of contemporary art that unfolds across the islands of Japan's...
Guests nationwide can enjoy a fresh topping and collectible sticker on July 31
ORLANDO, Fla., July 29, 2025 /PRNewswire/ -- National Avocado Day is the...
HOUSTON, July 29, 2025 /PRNewswire/ -- Bristow Group Inc. (NYSE: VTOL), the global leader in innovative and sustainable vertical flight solutions, today announced it...
Drivers and Fillers Join Growing Fight for Fair Contract, Demand End to Unfair Labor Practices
HONOLULU, July 29, 2025 /PRNewswire/ -- Teamsters at Airgas...